|
JP4320054B2
(ja)
*
|
1996-08-13 |
2009-08-26 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
ポリヌクレオチド送達のための組成物および方法
|
|
US6649362B2
(en)
*
|
1997-09-08 |
2003-11-18 |
Medvet Science Pty. Ltd. |
Screening method for an agent having an effect on a sphingosine kinase signaling pathway
|
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
|
ES2347027T3
(es)
|
1998-05-22 |
2010-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Moleculas bifuncionales y terapias basadas en las mismas.
|
|
US6355678B1
(en)
|
1998-06-29 |
2002-03-12 |
Parker Hughes Institute |
Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
|
|
GB9919713D0
(en)
*
|
1999-08-19 |
1999-10-20 |
Queen Mary & Westfield College |
New medical use of high density lipoprotein
|
|
DE10112926B4
(de)
*
|
2001-03-13 |
2005-11-10 |
Schebo Biotech Ag |
Verwendung von Aminooxyacetat zur Tumorbehandlung
|
|
GB0123571D0
(en)
|
2001-04-05 |
2001-11-21 |
Aventis Pharm Prod Inc |
Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
|
|
EP1381356B1
(en)
*
|
2001-04-05 |
2008-05-28 |
Aventis Pharmaceuticals Inc. |
Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
|
|
MXPA04000224A
(es)
|
2001-07-10 |
2005-07-25 |
4Sc Ag |
Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
|
|
JP4202250B2
(ja)
|
2001-07-25 |
2008-12-24 |
バイオマリン ファーマシューティカル インコーポレイテッド |
血液脳関門輸送を調節するための組成物および方法
|
|
CA2457840C
(en)
*
|
2001-08-20 |
2011-10-11 |
Zlb Bioplasma Ag |
Hdl for the treatment of stroke and other ischemic conditions
|
|
EP1285662A1
(en)
*
|
2001-08-20 |
2003-02-26 |
ZLB Bioplasma AG |
Reconstituted HDL for the treatment of stroke and ischemic conditions
|
|
US7368423B1
(en)
*
|
2001-12-05 |
2008-05-06 |
The Scripps Research Institute |
Composition and method for treating chronic allograft rejection
|
|
US7470659B2
(en)
|
2001-12-07 |
2008-12-30 |
The Regents Of The University Of California |
Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
|
|
JP2005511713A
(ja)
*
|
2001-12-07 |
2005-04-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア |
加齢性黄斑変性についての処置
|
|
US20030229062A1
(en)
*
|
2001-12-07 |
2003-12-11 |
The Regents Of The University Of California |
Treatments for age-related macular degeneration (AMD)
|
|
MXPA04010170A
(es)
*
|
2002-04-16 |
2005-02-03 |
Fujisawa Pharmaceutical Co |
Medicamento para prevenir y/o tratar el rechazo cronico.
|
|
MXPA05006890A
(es)
|
2002-12-23 |
2006-04-07 |
4Sc Ag |
Compuestos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
|
|
CA2584655A1
(en)
*
|
2004-10-19 |
2006-04-27 |
Aventis Pharmaceuticals Inc. |
Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
|
|
AU2005201035B2
(en)
*
|
2005-03-08 |
2012-04-26 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US7759315B2
(en)
*
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
EP2671507A3
(en)
|
2005-04-28 |
2014-02-19 |
Proteus Digital Health, Inc. |
Pharma-informatics system
|
|
US9062126B2
(en)
|
2005-09-16 |
2015-06-23 |
Raptor Pharmaceuticals Inc. |
Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
|
|
ES2319596B1
(es)
|
2006-12-22 |
2010-02-08 |
Laboratorios Almirall S.A. |
Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
|
|
UY31272A1
(es)
|
2007-08-10 |
2009-01-30 |
Almirall Lab |
Nuevos derivados de ácido azabifenilaminobenzoico
|
|
EP2100881A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Pyrimidyl- or pyridinylaminobenzoic acid derivatives
|
|
EP2135610A1
(en)
|
2008-06-20 |
2009-12-23 |
Laboratorios Almirall, S.A. |
Combination comprising DHODH inhibitors and methotrexate
|
|
CA2752373C
(en)
|
2009-02-20 |
2017-10-10 |
To-Bbb Holding B.V. |
Glutathione-based drug delivery system
|
|
EP2239256A1
(en)
|
2009-03-13 |
2010-10-13 |
Almirall, S.A. |
Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
|
|
IL255113B
(en)
|
2009-05-06 |
2022-09-01 |
Laboratory Skin Care Inc |
Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
|
|
EP2314577A1
(en)
|
2009-10-16 |
2011-04-27 |
Almirall, S.A. |
Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
|
|
UA108760C2
(uk)
|
2010-07-01 |
2015-06-10 |
|
Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
|
|
EP2444086A1
(en)
|
2010-10-22 |
2012-04-25 |
Almirall, S.A. |
Combinations comprising DHODH inhibitors and COX inhibitors
|
|
WO2012109329A2
(en)
|
2011-02-08 |
2012-08-16 |
Children's Medical Center Corporation |
Methods for treatment of melanoma
|
|
WO2019175396A1
(en)
|
2018-03-16 |
2019-09-19 |
Immunic Ag |
Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
|
|
EP3900717B1
(en)
|
2020-04-21 |
2024-11-20 |
Immunic AG |
Vidofludimus for use in the treatment or prevention of viral diseases
|